ASMB Stock Overview
Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Assembly Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.33 |
| 52 Week High | US$20.04 |
| 52 Week Low | US$7.69 |
| Beta | 0.61 |
| 1 Month Change | 12.68% |
| 3 Month Change | 29.32% |
| 1 Year Change | 12.83% |
| 3 Year Change | -74.58% |
| 5 Year Change | -92.92% |
| Change since IPO | -96.47% |
Recent News & Updates
Recent updates
Here's Why Assembly Biosciences (NASDAQ:ASMB) Must Use Its Cash Wisely
Aug 17
Will Assembly Biosciences (NASDAQ:ASMB) Spend Its Cash Wisely?
Feb 27We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate
Nov 09Jason Okazaki to succeed John McHutchison as Assembly Biosciences CEO at year-end
Oct 05Assembly Biosciences to discontinue development of inhibitor vebicorvir, cut workforce
Jul 20We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate
Jun 08We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate
Jan 11We're Keeping An Eye On Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate
Sep 03Assembly Biosciences announces resignation of CFO
Jun 02Time To Worry? Analysts Just Downgraded Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Outlook
Mar 24Assembly Biosciences' (NASDAQ:ASMB) Shareholders Are Down 86% On Their Shares
Feb 05We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely
Dec 14
Assembly Bio inks deal with Door Pharmaceuticals to develop HBV core protein modulators
Nov 16Assembly Biosciences EPS beats by $0.69, beats on revenue
Nov 05Shareholder Returns
| ASMB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.5% | -4.7% | -3.7% |
| 1Y | 12.8% | -2.7% | 20.2% |
Return vs Industry: ASMB exceeded the US Biotechs industry which returned -2% over the past year.
Return vs Market: ASMB underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| ASMB volatility | |
|---|---|
| ASMB Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ASMB's share price has been volatile over the past 3 months.
Volatility Over Time: ASMB's weekly volatility has decreased from 13% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 65 | Jason Okazaki | www.assemblybio.com |
Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company’s next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist.
Assembly Biosciences, Inc. Fundamentals Summary
| ASMB fundamental statistics | |
|---|---|
| Market cap | US$73.09m |
| Earnings (TTM) | -US$61.23m |
| Revenue (TTM) | US$7.16m |
10.2x
P/S Ratio-1.2x
P/E RatioIs ASMB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASMB income statement (TTM) | |
|---|---|
| Revenue | US$7.16m |
| Cost of Revenue | US$2.12m |
| Gross Profit | US$5.05m |
| Other Expenses | US$66.28m |
| Earnings | -US$61.23m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.17 |
| Gross Margin | 70.46% |
| Net Profit Margin | -854.78% |
| Debt/Equity Ratio | 0% |
How did ASMB perform over the long term?
See historical performance and comparison